| pubmed-article:10093693 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10093693 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:10093693 | lifeskim:mentions | umls-concept:C0006826 | lld:lifeskim |
| pubmed-article:10093693 | lifeskim:mentions | umls-concept:C0205208 | lld:lifeskim |
| pubmed-article:10093693 | lifeskim:mentions | umls-concept:C0016360 | lld:lifeskim |
| pubmed-article:10093693 | lifeskim:mentions | umls-concept:C0246415 | lld:lifeskim |
| pubmed-article:10093693 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
| pubmed-article:10093693 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:10093693 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:10093693 | pubmed:dateCreated | 1999-5-13 | lld:pubmed |
| pubmed-article:10093693 | pubmed:abstractText | This study was undertaken to evaluate the feasibility of administering docetaxel (Taxotere; Rhône-Poulenc-Rorer) as a one-hour intravenous (i.v.) infusion on day 1 combined with 5-fluorouracil (5-FU) as a bolus i.v. injection for five (days 1-5) or three (days 1-3) consecutive days every four weeks. | lld:pubmed |
| pubmed-article:10093693 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10093693 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10093693 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10093693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10093693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10093693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10093693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10093693 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10093693 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:10093693 | pubmed:issn | 0923-7534 | lld:pubmed |
| pubmed-article:10093693 | pubmed:author | pubmed-author:SmithLL | lld:pubmed |
| pubmed-article:10093693 | pubmed:author | pubmed-author:RodriguezGG | lld:pubmed |
| pubmed-article:10093693 | pubmed:author | pubmed-author:Von HoffD DDD | lld:pubmed |
| pubmed-article:10093693 | pubmed:author | pubmed-author:BurrilCC | lld:pubmed |
| pubmed-article:10093693 | pubmed:author | pubmed-author:RavdinPP | lld:pubmed |
| pubmed-article:10093693 | pubmed:author | pubmed-author:BelletRR | lld:pubmed |
| pubmed-article:10093693 | pubmed:author | pubmed-author:RowinskyE KEK | lld:pubmed |
| pubmed-article:10093693 | pubmed:author | pubmed-author:PetitTT | lld:pubmed |
| pubmed-article:10093693 | pubmed:author | pubmed-author:PeacockNN | lld:pubmed |
| pubmed-article:10093693 | pubmed:author | pubmed-author:SmetzerLL | lld:pubmed |
| pubmed-article:10093693 | pubmed:author | pubmed-author:AylesworthCC | lld:pubmed |
| pubmed-article:10093693 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10093693 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:10093693 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10093693 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10093693 | pubmed:pagination | 223-9 | lld:pubmed |
| pubmed-article:10093693 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10093693 | pubmed:meshHeading | pubmed-meshheading:10093693... | lld:pubmed |
| pubmed-article:10093693 | pubmed:meshHeading | pubmed-meshheading:10093693... | lld:pubmed |
| pubmed-article:10093693 | pubmed:meshHeading | pubmed-meshheading:10093693... | lld:pubmed |
| pubmed-article:10093693 | pubmed:meshHeading | pubmed-meshheading:10093693... | lld:pubmed |
| pubmed-article:10093693 | pubmed:meshHeading | pubmed-meshheading:10093693... | lld:pubmed |
| pubmed-article:10093693 | pubmed:meshHeading | pubmed-meshheading:10093693... | lld:pubmed |
| pubmed-article:10093693 | pubmed:meshHeading | pubmed-meshheading:10093693... | lld:pubmed |
| pubmed-article:10093693 | pubmed:meshHeading | pubmed-meshheading:10093693... | lld:pubmed |
| pubmed-article:10093693 | pubmed:meshHeading | pubmed-meshheading:10093693... | lld:pubmed |
| pubmed-article:10093693 | pubmed:meshHeading | pubmed-meshheading:10093693... | lld:pubmed |
| pubmed-article:10093693 | pubmed:meshHeading | pubmed-meshheading:10093693... | lld:pubmed |
| pubmed-article:10093693 | pubmed:meshHeading | pubmed-meshheading:10093693... | lld:pubmed |
| pubmed-article:10093693 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10093693 | pubmed:articleTitle | A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies. | lld:pubmed |
| pubmed-article:10093693 | pubmed:affiliation | Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, USA. | lld:pubmed |
| pubmed-article:10093693 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10093693 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10093693 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:10093693 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10093693 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10093693 | lld:pubmed |
